Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making
- Authors
- A Hochhaus
- A Hochhaus
- A Hochhaus
- A Hochhaus
- A Hughes
- A Nazha
- A Quintás-Cardama
- A Quintás-Cardama
- AB Patel
- AN Winn
- B Hanfstein
- B Hanfstein
- B Nagar
- C Schütz
- C Tanaka
- D Marin
- D Rea
- DA Arber
- DDH Kim
- DH Boschelli
- DM Ross
- DM Ross
- E Buchdunger
- E Jabbour
- E Jabbour
- E Weisberg
- F Castagnetti
- F-X Mahon
- G Etienne
- G Saglio
- Gabriela Hobbs
- H Kantarjian
- H Kantarjian
- HM Kantarjian
- HM Kantarjian
- J Cortes
- J Hasford
- J Imagawa
- James A. Kennedy
- JB Konopka
- JD Rowley
- JE Cortes
- JE Cortes
- JE Cortes
- JE Cortes
- JE Cortes
- JE Cortes
- JE Sokal
- JF Apperley
- JH Lipton
- JL Steegmann
- L Gorkin
- L Kalmanti
- M Baccarani
- M Baccarani
- M Danthala
- M Ilander
- M Pfirrmann
- M Puttini
- ME Gorre
- ML Lemos de
- MW Deininger
- N Bubnoff von
- NJ Donato
- NP Shah
- P Jain
- PW Manley
- S Branford
- S Faderl
- SB Dusetzina
- SG O’Brien
- T Hughes
- T O’Hare
- T O’Hare
- T Sacha
- TH Brümmendorf
- TP Hughes
- WS Pear
- WV Padula
- Publication date
- Publisher
- 'Springer Science and Business Media LLC'
- Doi